Science Metaverse Podcast

Nanome Inc.

Podcast about the Science Metaverse, Desci, everything in between and beyond read less
TechnologyTechnology

Episodes

EP 45: Collaborative Drug Design in XR hosted by Nanome
Dec 18 2022
EP 45: Collaborative Drug Design in XR hosted by Nanome
Tune in to see Application Scientists from Nanome discuss how drug design and discovery can be improved across teams using XR. From pocket characterization to docking, and more, teams from all over the world can still come together in the space through the power of XR toolsKeita FunakawaCOONanomeKeita Funakawa is Nanome's COO. Keita’s passion lies at the intersection of emerging technologies, digital arts, and science. He graduated from UC San Diego with a B.S. in Management Science (Quantitative Economics) and a minor in Visual Arts Digital Media. He co-founded Nanome in 2015 and now leads company operations.Mike BishopDrug Discovery ConsultantNanomeMike Bishop started Bishop Drug Discovery Consulting in 2019 after 26 years as a medicinal chemist with GSK. From 2001 to 2014 he directed a department of medicinal chemists and DMPK scientists with a focus on metabolic diseases, identifying ~10 clinical development candidates. From 2014 to 2019, Mike served as a Director in GSK’s Discovery Partnerships with Academia (DPAc) unit, with responsibilities for thorough vetting of research opportunities across multiple therapeutic areas, building collaborative workplans and leading joint research programs with academic investigators. Mike earned a B.A. in chemistry from Rice University in Houston, TX, worked in the petrochemical industry with Amoco Chemical in Texas City, TX for two years, and then returned to Rice, earning a Ph.D. in organic chemistry under the guidance of Dr. Marco Ciufolini.Jonathon GastSenior Application ScientistNanomeJonathon Gast has a background in pharmacology, informatics, and medicinal chemistry. He completed his Ph.D. in molecular pharmacology at Purdue University with a focus on the creation of informatic approaches for the determination of mechanisms of action of synthetic lethal combinations. As an applications scientist at Nanome, he communicates with customers to understand their research objectives to create novel solutions through Nanome. This includes the creation of customized software, on-site training, or online demonstrations.
EP34: Human 5HT-2A SNPs & pharmacological signaling alterations of classic psychedelics
Oct 3 2022
EP34: Human 5HT-2A SNPs & pharmacological signaling alterations of classic psychedelics
We are joined again by Dr. Asher Brandt, Professor of Biochemistry at the Saint Joseph University, Connecticut, specializing in psychedelic pharmacology. We discuss a recently published paper about how Single Nucleotide Polymorphisms, (SNPs, pronounced “snips”) might alter the pharmacological signaling of potentially therapeutic psychedelics.SNPs are the most common type of genetic variation among people. Specifically, it’s a genomic variant at a single base position in the DNA, which can lead to a single point amino acid mutation in the subsequently synthesized protein.In the study, the authors examined whether sequence variations in the 5-HT2A receptor gene affect the signaling of some of the most used psychedelic drugs such as LSD, mescalin, psilocybin. They examined the in vitro pharmacology of seven non-synonymous SNPs, which give rise to a variant of 5-HT2A serotonin receptors. What they found is that these non-synonymous SNPs exert statistically significant effects on not just the the efficacy but also the potency of four therapeutically relevant psychedelics.What’s mind blowing, in our opinion, is that the in vitro pharmacological effects of the SNP drug actions at 5-HT2A receptor are both amino acid and drug specific.References:Schmitz et al. (2022). 5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics. ACS Chem. Neurosci. 2022, 13, 16, 2386–2398.NCBI SNPs Database (dbSNP) url: https://www.ncbi.nlm.nih.gov/snp/